Last reviewed · How we verify
Xuezhikang capsule — Competitive Intelligence Brief
marketed
Herbal lipid-lowering agent; statin-containing traditional Chinese medicine
Cardiovascular
Small molecule
Live · refreshed every 30 min
Target snapshot
Xuezhikang capsule (Xuezhikang capsule) — China Academy of Chinese Medical Sciences. Xuezhikang reduces blood lipids and improves blood circulation by inhibiting cholesterol synthesis and modulating lipid metabolism through its active compounds derived from red yeast rice.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Xuezhikang capsule TARGET | Xuezhikang capsule | China Academy of Chinese Medical Sciences | marketed | Herbal lipid-lowering agent; statin-containing traditional Chinese medicine |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Herbal lipid-lowering agent; statin-containing traditional Chinese medicine class)
- China Academy of Chinese Medical Sciences · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Xuezhikang capsule CI watch — RSS
- Xuezhikang capsule CI watch — Atom
- Xuezhikang capsule CI watch — JSON
- Xuezhikang capsule alone — RSS
- Whole Herbal lipid-lowering agent; statin-containing traditional Chinese medicine class — RSS
Cite this brief
Drug Landscape (2026). Xuezhikang capsule — Competitive Intelligence Brief. https://druglandscape.com/ci/xuezhikang-capsule. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab